Crescent Biopharma (CBIO) Stock Forecast & Price Target

Compare

1,020 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CBIO Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Crescent

Biopharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CBIO Stock 12 Month Forecast

Average Price Target

$30.14

▲(156.73% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Crescent Biopharma in the last 3 months. The average price target is $30.14 with a high forecast of $35.00 and a low forecast of $22.00. The average price target represents a 156.73% change from the last price of $11.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","39":"$39","15.75":"$15.75","23.5":"$23.5","31.25":"$31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.75,23.5,31.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.82,11.756923076923076,13.693846153846154,15.630769230769232,17.567692307692308,19.504615384615384,21.441538461538464,23.37846153846154,25.315384615384616,27.252307692307692,29.189230769230768,31.126153846153848,33.06307692307692,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.82,11.383076923076924,12.946153846153846,14.509230769230768,16.072307692307692,17.635384615384616,19.198461538461537,20.76153846153846,22.324615384615385,23.88769230769231,25.450769230769232,27.013846153846153,28.576923076923077,{"y":30.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.82,10.756923076923076,11.693846153846154,12.63076923076923,13.567692307692308,14.504615384615384,15.44153846153846,16.378461538461536,17.315384615384616,18.252307692307692,19.189230769230768,20.126153846153848,21.06307692307692,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.26,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.94,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.82,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.18,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.11,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.2,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.82,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$30.14

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

$25

Buy

112.95%

Upside

Reiterated

02/19/26

Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target

Biren Amin

Piper Sandler

$35

Buy

198.13%

Upside

Reiterated

02/19/26

Piper Sandler Sticks to Its Buy Rating for Crescent Biopharma (CBIO)

Charles Zhu

LifeSci Capital

$22

Buy

87.39%

Upside

Reiterated

02/18/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bradley Canino

Guggenheim

$35

Buy

198.13%

Upside

Initiated

01/21/26

Crescent Biopharma (CBIO) Initiated with a Buy at Guggenheim

Robert Driscoll

Wedbush

$27

Buy

129.98%

Upside

Initiated

12/18/25

Wedbush Reaffirms Their Buy Rating on Crescent Biopharma (CBIO)

Akash Tewari

Jefferies

$35

Buy

198.13%

Upside

Reiterated

12/05/25

Jefferies Sticks to Its Buy Rating for Crescent Biopharma (CBIO)

Stephen Willey

Stifel Nicolaus

$28→$32

Buy

172.57%

Upside

Reiterated

12/04/25

Crescent Biopharma's Strategic Growth and Competitive Edge Justify Buy Rating

Phil Nadeau

TD Cowen

Buy

―

Reiterated

11/06/25

Crescent Biopharma's Promising Pipeline and Strategic Progress Drive Buy Rating

Eric Schmidt FCA

Cantor Fitzgerald

Buy

―

Initiated

03/21/25

Crescent Biopharma initiated with an Overweight at Cantor FitzgeraldCrescent Biopharma initiated with an Overweight at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

$25

Buy

112.95%

Upside

Reiterated

02/19/26

Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target

Biren Amin

Piper Sandler

$35

Buy

198.13%

Upside

Reiterated

02/19/26

Piper Sandler Sticks to Its Buy Rating for Crescent Biopharma (CBIO)

Charles Zhu

LifeSci Capital

$22

Buy

87.39%

Upside

Reiterated

02/18/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bradley Canino

Guggenheim

$35

Buy

198.13%

Upside

Initiated

01/21/26

Crescent Biopharma (CBIO) Initiated with a Buy at Guggenheim

Robert Driscoll

Wedbush

$27

Buy

129.98%

Upside

Initiated

12/18/25

Wedbush Reaffirms Their Buy Rating on Crescent Biopharma (CBIO)

Akash Tewari

Jefferies

$35

Buy

198.13%

Upside

Reiterated

12/05/25

Jefferies Sticks to Its Buy Rating for Crescent Biopharma (CBIO)

Stephen Willey

Stifel Nicolaus

$28→$32

Buy

172.57%

Upside

Reiterated

12/04/25

Crescent Biopharma's Strategic Growth and Competitive Edge Justify Buy Rating

Phil Nadeau

TD Cowen

Buy

―

Reiterated

11/06/25

Crescent Biopharma's Promising Pipeline and Strategic Progress Drive Buy Rating

Eric Schmidt FCA

Cantor Fitzgerald

Buy

―

Initiated

03/21/25

Crescent Biopharma initiated with an Overweight at Cantor FitzgeraldCrescent Biopharma initiated with an Overweight at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crescent Biopharma

3 Months

xxx

Success Rate

5/12 ratings generated profit

Average Return

-5.48%

initiated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -5.48% per trade.

1 Year

Biren AminPiper Sandler

Success Rate

7/12 ratings generated profit

Average Return

+19.51%

initiated a buy rating 24 days ago

Copying Biren Amin's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +19.51% per trade.

2 Years

xxx

Success Rate

8/12 ratings generated profit

Average Return

+54.36%

initiated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +54.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CBIO Analyst Recommendation Trends

Rating

Aug 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CBIO has received 9 Buy Ratings, 37 Hold Ratings, and 8 Sell Ratings. CBIO average Analyst price target in the past 3 months is 30.14.

Each month's total comprises the sum of three months' worth of ratings.

CBIO Financial Forecast

CBIO Earnings Forecast

The previous quarter’s earnings for CBIO were -$1.27.

CBIO Sales Forecast

The previous quarter’s earnings for CBIO were $0.00.

CBIO Stock Forecast FAQ

What is CBIO’s average 12-month price target, according to analysts?

Based on analyst ratings, Crescent Biopharma’s 12-month average price target is 30.14.

What is CBIO’s upside potential, based on the analysts’ average price target?

Crescent Biopharma has 156.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CBIO a Buy, Sell or Hold?

Crescent Biopharma has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Crescent Biopharma’s price target?

The average price target for Crescent Biopharma is 30.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $22.00. The average price target represents 156.73% Increase from the current price of $11.74.

What do analysts say about Crescent Biopharma?

Crescent Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of CBIO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Crescent Biopharma (CBIO) Stock Forecast & Price Target

CBIO Analyst Ratings

CBIO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crescent Biopharma

CBIO Analyst Recommendation Trends

CBIO Financial Forecast

CBIO Earnings Forecast

CBIO Sales Forecast

CBIO Stock Forecast FAQ

Detailed List of Analyst Forecasts